Does the biotech sector in Spain need to concentrate?

Integral service around a transaction
BY : Diego GutiérrezFebruary Fri, 2015
biotechnology in Spain2014 has been a good year for the biotech sector in Spain, mainly due to the improvement in public-private collaboration that is being consolidated in the sector. Several acquisitions and mergers have taken place and new venture capital funds focused on biotechnology have appeared.


La biotecnología española se dirige hacia la concentración

Uno de los retos que tiene sobre la mesa el sector biotecnológico español es el de afrontar su atomización y alcanzar dimensión crítica para su crecimiento, principalmente, internacional.  A día a de hoy hay cerca de 600 empresas, la mayor parte pequeñas y medianas que tienen la biotecnología como actividad principal, esto dificulta mucho su visibilidad.

Si bien es cierto que el año 2014 se han realizado varias adquisiciones precisamente con este fin, como la compra de la vasca  Biophenix, que desarrolla screening de fármacos  por parte de Bionaturis, que desarrolla medicamentos biológicos, la adquisición de Kiro-Robotics por parte del gigante Grifols o la compra que ha realizado Natraceutical del laboratorio Reig Jofre, laboratorio francés con presencia en Europa y en EEUU. Además en el año 2015 también se ha anunciado la compra de la francesa Trophos por parte de Roche por  €120 M, a los que se podrían sumar otros 350M en función de hitos. Trophos dispone de una molécula propia, TRO19622, que está siendo investigada en pacientes con atrofia muscular espinal (SMA), 

BioSpain 2014 ha sido un importante foro de encuentro para hacer negocios, con más de 200 expositores y con 50 inversores, el 80 por ciento de ellos internacionales.

“El sector farmacéutico camina hacia la consolidación de un mapa integrado por pocos laboratorios y más grandes” afirma Diego Gutiérrez socio de Abra-Invest.

Otros retos para el 2015

Entre los retos para el 2015 se encuentran la necesidad de inversores internacionales en empresas españolas, que nos permitan competir con las grandes a nivel mundial.Este año ya se han realizado inversiones internacionales en España como la inversión de €3M de la multinacional japonesa Yamada BeeFarm 3 en la empresa española Life Length. 

Además otro de los retos consiste en  aliviar el endeudamiento público en el sector biotecnológico y tomar medidas que apoyen a las pymes para salir de la crisis.

 Other posts that may interest you

New developments in biotech funds in Spain (En-2015)

Juan Diego Cuenca, partner of Abra-invest, analyses the biotechnology sector on Gestionaradio

M&A deals in biotech companies in Spain are on the rise

The M&A Professionals

Meet our services


Do you want to be up to date?


Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?